Synovitis
Methodology & AI Transparency ⓘ
Synovitis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Osteoarthritis, Gout & Joint Pain practice, Synovitis (ICD-10 M65.90) is stratified through serum urate/inflammatory marker in Synovitis (M65.90: profiling), pairing targeted symptom control with longitudinal Weight-Bearing Joint Radiograph [Synovitis M65.90] surveillance.
- 2 Real-world patient consensus: Mapped to Osteoarthritis, Gout & Joint Pain under ICD-10-CM M65.90 for Synovitis clinical workups.
- 3 Typical cash cost range: Primary evaluation for Synovitis incorporates serum urate/inflammatory marker in Synovitis (M65.90: profiling) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Synovitis: maintaining hs-CRP & Erythrocyte in Synovitis (M65.90: Sedimentation Rate) within hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M65.90).
Ask our AI Specialists anything about Synovitis
What Is Synovitis?
Within Osteoarthritis, Gout & Joint Pain practice, Synovitis (ICD-10 M65.90) is stratified through serum urate/inflammatory marker in Synovitis (M65.90: profiling), pairing targeted symptom control with longitudinal Weight-Bearing Joint Radiograph [Synovitis M65.90] surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Synovitis (code M65.90) is low-grade synovial metalloproteinase in Synovitis (M65.90: release), which Osteoarthritis, Gout & Joint Pain clinicians address while surveilling hs-CRP & Erythrocyte in Synovitis (M65.90: Sedimentation Rate) (hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M65.90)).
Common Symptoms & Clinical Signs
- • Presentation of Synovitis (M65.90): sudden, intensely painful, in Synovitis (M65.90: red swollen big-toe)
- • Secondary Synovitis clinical sign: localized tendon or in Synovitis (M65.90: bursa tenderness limiting)
- • Symptom flares in Synovitis correlating with hs-CRP & Erythrocyte in Synovitis (M65.90: Sedimentation Rate) deviation outside hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M65.90)
- • Functional arthritis & joints impact requiring serum urate/inflammatory marker in Synovitis (M65.90: profiling) evaluation (M65.90)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Synovitis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M65.90 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Synovitis (M65.90: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M65.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Synovitis M65.90] | Preserved joint-space width (M65.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Synovitis (M65.90: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M65.90) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Synovitis
Treatment selection for Synovitis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Synovitis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Clinimetric Validation of the Assessment of Spondyloarthritis International: What a 341-Participant Study Found The ASAS HI demonstrated reliability, construct validity, known groups discrimination, and responsiveness in adults with r-axSpA in 2 clinical trials. The Journal of rheumatology • 2023-06-15 • Phase III Randomized Trial | N = 341 | 93/100 | PMID 36725056 ↗ |
| New Insights on Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent: What a 381-Participant Study Found In patients with active RA who received ozoralizumab in combination with MTX, the signs and symptoms of RA were significantly reduced as compared with the outcomes in those receiving placebo. Arthritis & rheumatology (Hoboken, N.J.) • 2022-11-15 • Phase III Randomized Trial | N = 381 | 93/100 | PMID 35729713 ↗ |
| Can This Approach Help? Inside the Latest Research on Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic This unique ultrasound study shows that apart from improving the signs and symptoms of PsA, IL-17A inhibition with secukinumab leads to a rapid and significant reduction of synovitis in PsA patients. Rheumatology (Oxford, England) • 2022-05-05 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34528079 ↗ |
| Can This Approach Help? Inside the Latest Research on Rapid and sustained improvements in patient-reported signs and symptoms with Patients treated with IXE versus PBO achieved significantly greater improvements and showed faster onset of improvements in patient-reported outcomes measuring symptoms and impact of PsA. Clinical and experimental rheumatology • 2021-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 32573426 ↗ |
Synovitis Patient Community & “People Like Me” Threads
Filter Synovitis community threads and patient logs by age, biological sex, dosage, and treatment duration.